Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: Importance of myeloid-derived suppressor cells

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Karakhanova, Svetlana ^a   Link, Julia ^a   Heinrich, Moritz ^a   Shevchenko, Ivan ^a   Yang, Yuhui ^a,b   Hassenpflug, Matthias ^a   Bunge, Henriette ^a   Von Ahn, Katharina ^a   Brecht, Ramona ^a   Mathes, Andreas ^a   Maier, Caroline ^a   Umansky, Viktor ^a   Werner, Jens ^c   Bazhin, Alexandr V ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Immune suppression; MDSC; Orthotopic Panc02 model; Pancreatic adenocarcinoma

Indexed keywords

ALPHA1 INTERFERON; INTERLEUKIN 1BETA; PHOSPHODIESTERASE V; SILDENAFIL; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LYMPHOCYTE FUNCTION; MACROPHAGE; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; MYELOID LEUKOCYTE; NONHUMAN; PANCREAS ADENOCARCINOMA; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 84944276547     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.998519     Document Type: Article

References (41)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326:455-65; PMID:1732772; http://dx. doi. org/10. 1056/ NEJM199202133260706
2. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17:403-9; PMID:16596292; http://dx. doi. org/10. 1007/s10552-005-0539-4
3. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16:37-52; PMID:12063828; http://dx. doi. org/10. 1016/ S0889-8588(01)00007-7
4. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013; 62:317-26; PMID:23112132; http://dx. doi. org/10. 1136/gutjnl-2012-303588
5. Bazhin AV, Shevchenko I, Umansky V, Werner J, Karakhanova S. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother 2014; 63:59-65; PMID:24129765; http://dx. doi. org/10. 1007/s00262-013-1485-8
6. Bazhin AV, Bayry J, Umansky V, Werner J, Karakhanova S. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncoimmunology 2013; 2:e25736; PMID:24327934; http://dx. doi. org/10. 4161/onci. 25736
7. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, Laschinger M, W Büchler M, Friess H. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 2008; 268:98-109; PMID:18486325; http://dx. doi. org/10. 1016/j. canlet. 2008. 03. 056
8. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin AV. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013; 133:98-107; PMID:23233419; http://dx. doi. org/10. 1002/ijc. 27990
9. Bellone G, Carbone A, Smirne C, Scirelli T, Buffolino A, Novarino A, Stacchini A, Bertetto O, Palestro G, Sorio C et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 2006; 177:3448-60; PMID:16920987; http://dx. doi. org/10. 4049/jimmunol. 177. 5. 3448
10. Wormann SM, Diakopoulos KN, Lesina M, Algul H. The immune network in pancreatic cancer development and progression. Oncogene 2014; 33:2956-67; PMID:23851493; http://dx. doi. org/10. 1038/onc. 2013. 257
11. Helm O, Held-Feindt J, Grage-Griebenow E, Reiling N, Ungefroren H, Vogel I, Krüger U, Becker T, Ebsen M, Röcken C et al. Tumor-associated macrophages exhibit pro-and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. Int J Cancer 2014; 135:843-61; PMID:24458546; http://dx. doi. org/10. 1002/ijc. 28736
12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http:// dx. doi. org/10. 1038/nri2506
13. Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009; 128:141-9; PMID:19689743; http://dx. doi. org/ 10. 1111/j. 1365-2567. 2009. 03105. x
14. Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets 2011; 11:734-51; PMID:21599634; http://dx. doi. org/10. 2174/156800911796191024
15. Ghansah T. A novel strategy for modulation of MDSC to enhance cancer immunotherapy. Oncoimmunology 2012; 1:984-5; PMID:23162780; http://dx. doi. org/ 10. 4161/onci. 20201
16. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67:9518-27; PMID:17909062; http://dx. doi. org/10. 1158/0008-5472. CAN-07-0175
17. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21644036; http://dx. doi. org/10. 1007/s00262-011-1028-0
18. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M et al. Chronic inflammation promotes myeloidderived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A 2011; 108:17111-6; PMID:21969559; http://dx. doi. org/10. 1073/pnas. 1108 121108
19. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, Bayry J. Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nat Commun 2014; 5:4092; PMID:24910129; http://dx. doi. org/ 10. 1038/ncomms5092
20. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6:1755-66; PMID:10815894
21. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011; 41:2522-5; PMID:21952810; http://dx. doi. org/ 10. 1002/eji. 201141894
22. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-66; PMID:9834220
23. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55:15-35; discussion-6; PMID:11036931
24. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx. doi. org/10. 4049/jimmunol. 0802740
25. Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 2012; 61:1373-85; PMID:22215137; http://dx. doi. org/10. 1007/s00262-011-1178-0
26. Bunt SK, Mohr AM, Bailey JM, Grandgenett PM, Hollingsworth MA. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunol Immunother 2013; 62:225-36; PMID:22864396; http://dx. doi. org/10. 1007/s00262-012-1324-3
27. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; http://dx. doi. org/10. 4049/jimmunol. 181. 8. 5791
28. Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep 2012; 28:453-8; PMID:22614133; http:// dx. doi. org/10. 3892/or. 2012. 1812
29. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5:689-702; PMID:16883306; http://dx. doi. org/ 10. 1038/nrd2030
30. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; PMID:17101732; http://dx. doi. org/10. 1084/jem. 20061104
31. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in Bcell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439-49; PMID:18593947; http://dx. doi. org/10. 1158/0008-5472. CAN-07-6621
32. Karakhanova S, Yang Y, Link J, Soltek S, von Ahn K, Umansky V, Werner J, Bazhin AV. Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice. Mol Immunol 2013; 56:649-59; PMID:23911424; http://dx. doi. org/ 10. 1016/j. molimm. 2013. 06. 021
33. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8:737-44; PMID:18728636; http://dx. doi. org/ 10. 1038/nri2394
34. Klein SL. Immune cells have sex and so should journal articles. Endocrinology 2012; 153:2544-50; PMID:22434079; http://dx. doi. org/10. 1210/en. 2011-2120
35. Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 2010; 10:594-604; PMID:20651746; http://dx. doi. org/10. 1038/nri2815
36. Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Fernandez-Santos JM, Martin-Lacave I, Rubio A, Guerrero JM, Osuna C. Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/ Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 2006; 147:1717-24; PMID:16373423; http://dx. doi. org/10. 1210/en. 2005-0648
37. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48; PMID:15771580; http://dx. doi. org/10. 1146/annurev. immunol. 23. 021704. 115611
38. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44:717-26; PMID:6692374
39. Yang Y, Karakhanova S, Soltek S, Werner J, Philippov PP, Bazhin AV. In vivo immunoregulatory properties of the novel mitochondria-targeted antioxidant SkQ1. Mol Immunol 2012; 52:19-29; PMID:22591624; http://dx. doi. org/10. 1016/j. molimm. 2012. 04. 010
40. Karakhanova S, Meisel S, Ring S, Mahnke K, Enk AH. ERK/p38MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets. Eur J Immunol 2010; 40:254-66; PMID:19830728; http://dx. doi. org/10. 1002/eji. 200939289
41. Karakhanova S, Golovastova M, Philippov PP, Werner J, Bazhin AV. Interlude of cGMP and cGMP/protein kinase G type 1 in pancreatic adenocarcinoma cells. Pancreas 2014; 43:784-94; PMID:24826884; http:// dx. doi. org/10. 1097/MPA. 0000000000000104